At VMworld 2021, VMware revealed Project Capitola – a technology preview of software they are developing to aggregate heterogeneous memory tiers into a uniform, virtualized memory layer for vSphere environments.
In this podcast, Enrico Signoretti, Senior Data Storage Analyst at Gigaom, explores the benefits and future of Big Memory Computing adoption and CXL with Charles Fan, Founder and CEO at MemVerge.
The 20th annual Bio-IT World will highlight how Memory Machine software is accelerating discovery.
Webinar Replay August 12 was a big day for MemVerge. It was World Elephant Day, a day that brings the world together to help elephants, our Big Memory mascot. It was also a day that MemVerge and Penguin Computing hosted a webinar titled, “Endless Memory: In search of...
At useR! 2021, The R Conference, representatives from Analytical Biosciences, MemVerge and The Translational Genomics Research Institute (TGen) talk about the underlying technology and bioinformatic use cases.
AI/ML, analytics, graphic processing, and several other memory-intensive workloads are pushing the limits of current memory infrastructure, and new infrastructure techniques have arisen that, we believe, will combine to create an entirely new infrastructure market: Network Attached Memory.
Using MemVerge’s memory snapshots and clones allows parallel use of in-memory datasets in ways that are difficult, if not impossible, using traditional techniques.
Memverge’s memory snapshots bring a tried and trusted mechanism from storage arrays into the big memory era. Memory snapshots open up a range of new workflow possibilities that provide non-linear benefits to organizations that use large datasets every day. With memory snapshots, moving data to storage becomes a choice rather than a limitation.
Micron exiting the 3D XPoint market has the IT industry wondering what this means to the future of persistent memory (PMEM) and Big Memory Computing consisting of DRAM, PMEM, and memory virtualization software.
Today’s need for better compute platforms able to improve genomic analysis is acute, and it will only remain so in the years to come. This won’t be our last virus emergency. The need for more and better genomic analysis platforms will remain acute long beyond SARS-CoV-2.